Name: | Isradipine |
---|---|
PubChem Compound ID: | 158617 |
Description: | A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure. |
Molecular formula: | C19H21N3O5 |
Molecular weight: | 371.387 g/mol |
Synonyms: |
84260-64-0; NCGC00016931-01; NCGC00025341-01; Tocris-2004; CAS-75695-93-1; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (4S)-
|
Name: | Isradipine |
---|---|
Name (isomeric): | DB00270 |
Drug Type: | small molecule |
Description: | A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure. |
Synonyms: |
Isrodipine; Isradipino [Spanish]; Isradipinum [Latin]; (+/-)-Isradipine; Isradipin
|
Brand: | Clivoten, Prescal, Dynacrine, DynaCirc, Lomir, Rebriden, Esradin, DynaCire, Dynacirc CR, DynaCire CR |
Category: | Vasodilator Agents, Calcium Channel Blockers, Antihypertensive Agents |
CAS number: | 75695-93-1 |
Indication: | For the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics. |
---|---|
Pharmacology: |
Isradipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes ...
show more » |
Mechanism of Action: |
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to ot...
show more » |
Absorption: | Isradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%. |
Protein binding: | 95% |
Biotransformation: | Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine. |
Route of elimination: | Approximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces. |
Half Life: | 8 hours |
Toxicity: | Symptoms of overdose include lethargy, sinus tachycardia, and transient hypotension. Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|